DMSO for Health & Longevity - Quick Reference Sheet

DMSO for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

DMSO (dimethyl sulfoxide) is an inexpensive industrial solvent, also sold as topical gels and liquids and promoted for pain and inflammation. Its one approved medical use is a bladder treatment for a chronic painful bladder condition, unrelated to general health. No human data show longer life or more healthy years; topical pain relief is inconsistent. Garlic-like odor, skin irritation, and headache are well documented; product purity matters. (Full Review)

Protocol

Approved medical protocol
50 mL of 50% aqueous DMSO (Rimso-50)
Instilled by catheter, retained about 15 minutes, repeated every two weeks until maximal relief, then spaced further
Pharmaceutical skin protocol
Diclofenac 1.5% in a DMSO vehicle
40 drops applied to the knee four times daily for 12 weeks in a large trial
Trial-tested skin strengths
10% gel, 50% cream, 70% solution
10% gel three times daily for 14 days in tendon pain; 50% cream for two months in regional pain; 70% solution in tendon and ulcer trials
Time to effect
Interstitial cystitis (bladder)
Repeated treatments
Bladder relief needed treatments every two weeks
Tendon pain
3–7 days
Improvement on 10% gel
Knee osteoarthritis pain
3–4 weeks
Assessment window in knee osteoarthritis trials

Benefits

Contraindications
  • Pregnancy at any stage and breastfeeding
  • Children and adolescents under 18 years
  • Known DMSO hypersensitivity or a prior anaphylactoid (allergic-type, potentially severe) reaction
  • Urinary tract cancer, for bladder instillation
  • History of intracerebral hemorrhage (bleeding within the brain), or active anticoagulant therapy with an INR (blood-clotting test) above the prescribed target, for oral or large-area use (conservative precaution, not derived from trials)
  • Severe kidney or liver disease, such as eGFR (kidney filtration rate) below 30 mL/min/1.73 m² or Child-Pugh Class C (severe cirrhosis), for repeated use (conservative threshold, not derived from trials)
  • Open wounds or broken skin at the application site (theoretical)
Key Interactions
  • Topical corticosteroids (hydrocortisone, clobetasol, triamcinolone)
  • Topical nonsteroidal anti-inflammatory drugs (diclofenac, ketoprofen)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel; theoretical, oral or large-area use)
  • Other skin-applied prescription drugs (tretinoin, minoxidil, tacrolimus)
  • Sedatives (zolpidem; benzodiazepines such as lorazepam; theoretical)
  • Aspirin and over-the-counter anti-inflammatories (ibuprofen, naproxen; theoretical, regular use with oral DMSO)
  • Skin products (hydrocortisone cream, capsaicin, menthol or methyl salicylate rubs, sunscreen, insect repellent)
  • Supplements with antiplatelet effects (fish oil, ginkgo, vitamin E, garlic extract; theoretical, oral DMSO)
  • Oral methylsulfonylmethane (low concern)
  • Oil and botanical mixtures (castor oil, black seed oil, essential oils)
  • Heat wraps, occlusive dressings, microneedling, or laser on the same skin (theoretical)

Risk & Side Effects

  • High: Garlic-like breath, taste, and body odor; skin reactions; headache and gastrointestinal upset; bladder irritation during instillation
  • Medium: Allergic and histamine-type reactions; reactions to infused DMSO
  • Low: Bleeding risk
  • Speculative: Eye lens changes; brain cell injury in animal and cell studies; reproductive and developmental toxicity in animals; contaminants and unintended absorption

Monitoring

Marker Target Why
ALT 10–30 U/L Liver safety
AST 10–30 U/L Liver safety
eGFR and creatinine eGFR 90 mL/min/1.73 m² or higher Kidney clearance of DMSO
Complete blood count Hemoglobin 13–16 g/dL; platelets 150–350 ×10⁹/L Detect hemolysis (red blood cell breakdown) or bleeding tendency
Urinalysis No blood or hemoglobin Detect hemolysis (red blood cell breakdown) after high-dose or infused exposure
Slit-lamp lens examination No established target; track no new lens opacity or refractive shift from baseline Animal lens changes prompted label advice
INR Within the individual's prescribed target (for example 2.0–3.0 for warfarin) Bleeding risk if on anticoagulants

Cadence: Baseline before any sustained or repeated use; then at 4 weeks, at 3 months, and every 6 months while use continues, and sooner if allergy, bleeding, or vision changes appear

Qualitative Assessment

  • Pain intensity (0–10 scale) and function, such as stiffness, walking, or grip
  • Skin condition at the site: redness, dryness, itching, urticaria (hives)
  • Odor duration, headache, and gastrointestinal upset
  • Sleep quality, energy, sedation, or dizziness